Publications

15 Nov 2018
Book

Can the Global Food Industry Overcome Public Distrust?

JamesBrey Food is the largest segment of the global economy. It is also widely recognized as more critical for human health than any pharmaceutical drug on the planet. But significant changes in the industry are making people lose trust in many institutions involved in... View Details

Keywords: by Sean Silverthorne; Agriculture & Agribusiness

Web

Recruiting Partners - Health Care

Pharmaceuticals Alpha Edison AMAG Pharmaceuticals Amarin Corporation American Tinnitus Association American Well AmerisourceBergen Amgen, Inc. Amicoat AS Amicus Therapeutics Amnisure International LLC... View Details

31 Oct 2023
News

Securing a Resilient Future for Senegal

Special Drawing Rights (international reserve assets that supplement a country’s official reserves); and negotiating agreements to fund some of flagship projects laid out in the 2019–2023 Priority Action Plan, a development model that supports growth through economic... View Details

01 Feb 2022
Book

Innovation Isn’t Just for Startups: How Big Companies Can Succeed

traditional core. She hired computational chemists, genetic scientists, and pharmaceutical business experts. They dressed and spoke differently from the famously staid IBM executive. The best Corporate Explorers not only disrupt the... View Details

Keywords: by Lane Lambert

10 Apr 2014
Research & Ideas

John Kotter’s Plan to Accelerate Your Business

other more rational. In a typical organization—from the federal government to a pharmaceutical giant—a hierarchical operational structure meets daily demands through clear reporting relationships and responsibilities, Kotter writes. This... View Details

Keywords: by Kim Girard

December 2019
Case

The Business of Pain: Johnson & Johnson and the Promise of Opioids

By: Erik Snowberg, Trevor Fetter and Amy W. Schulman

This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details

Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry

March 2023
Case

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details

28 Jul 2008
Research & Ideas

Making the Decision to Franchise (or not)

appears to be true when you get a new type of consumer for the same product." In the pharmaceutical industry, for example, selling medicine to both an independent general practitioner and a hospital will require a different organizational... View Details

Keywords: by Julia Hanna; Retail

February 2024
Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu

This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details

Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom

February 2010 (Revised September 2011)
Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain

Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details

Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland

October 2022
Case

Cost Plus Drugs

By: Alexander MacKay and James Barnett

In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details

Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Pharmaceutical Industry; Pharmaceutical Industry; United States; Texas

Elon Kohlberg is the Royal Little Professor of Business Administration at the Harvard Business School. His research is mainly in Game Theory, in particular the study of non-cooperative equilibrium.

Professor Kohlberg has taught many courses in the MBA,... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

01 Dec 2019
News

Remix

exercise of getting the mix just right “had almost a pharmaceutical effect on me,” she says. Hip-hop, though, hit a nerve. “I liked the nerdy braininess of digging into the lyrics and wordplay, but it also mashed up the soundtrack of my... View Details

Keywords: Jen McFarland Flint; photographed by Chris Sorensen; #MeToo; DefJam; Arts, Entertainment

September 2010 (Revised July 2013)
Case

Alnylam Pharmaceuticals: Building Value from the IP Estate

By: Willy C. Shih and Sen Chai

The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details

Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

September 1990 (Revised November 1991)
Case

Merck & Co., Inc. (B)

In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major... View Details

Keywords: Performance Evaluation; Compensation and Benefits; Pharmaceutical Industry